Article: article from journal or magazin.
Phase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with montanide ISA 720 or montanide ISA 51.
American Journal of Tropical Medicine and Hygiene
We assessed the safety, tolerability, and immunogenicity of a mixture of three synthetic peptides derived from the Plasmodium vivax circumsporozoite protein formulated in Montanide ISA 720 or Montanide ISA 51. Forty healthy malaria-naive volunteers were allocated to five experimental groups (A-E): four groups (A-D) were immunized intramuscularly with 50 and 100 μg/dose injections of a mixture of N, R, and C peptides formulated in the two different adjuvants at 0, 2, and 4 months and one group was administered placebo. Vaccines were immunogenic, safe, well tolerated, and no serious adverse events related to the vaccine occurred. Seroconversion occurred in > 90% of the vaccines and antibodies recognized the sporozoite protein on immunofluorescent antibody test. Vaccines in Montanide ISA 51 showed a higher sporozoite protein recognition and interferon production. Results encourage further testing of the vaccine protective efficacy.
Adjuvants, Immunologic/administration & dosage, Adolescent, Adult, Animals, Antibodies, Protozoan/blood, Dose-Response Relationship, Immunologic, Drug Toxicity, Female, Humans, Immunoglobulin G/blood, Injections, Intramuscular, Interferon-gamma/metabolism, Leukocytes, Mononuclear/metabolism, Malaria Vaccines/adverse effects, Malaria Vaccines/immunology, Malaria, Vivax/prevention & control, Male, Mannitol/administration & dosage, Mannitol/analogs & derivatives, Oleic Acids/administration & dosage, Plasmodium vivax/immunology, Protozoan Proteins/immunology, Time Factors
Web of science
Last modification date